29 results
10-KT
EYPT
EyePoint Pharmaceuticals Inc
18 Mar 19
Annual report (with FYE transition)
5:30pm
to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.
Our current … receiving an FDA debarment could result in a loss of business from third parties and severe reputational harm.
Although we have adopted a Code of Business
424B3
2nb32 y3klv
17 Mar 14
Prospectus supplement
12:00am
424B5
byu1ar f3diftr
20 Dec 13
Prospectus supplement for primary offering
12:00am
424B5
g492ehxtncd832pqjb4d
19 Jul 13
Prospectus supplement for primary offering
12:00am
424B5
v02nb1g2n7ahga5wptz
18 Jul 13
Prospectus supplement for primary offering
12:00am
424B5
9jot6h2u 8d0d50buy
2 Aug 12
Prospectus supplement for primary offering
12:00am